Neuropeptide Y
Neuropeptide Y (NPY)
Neuropeptide Y (NPY) is a 36-amino acid peptide neurotransmitter widely expressed in the central and peripheral nervous systems, playing a central role in energy homeostasis, appetite regulation, stress response, and circadian rhythm modulation. It is primarily studied in research contexts for its potent orexigenic (appetite-stimulating) effects, anxiolytic properties, and potential roles in resilience to stress-related disorders such as PTSD and depression. NPY has also attracted interest in cardiometabolic research due to its vasoconstrictor and adipogenic signaling roles.
Mechanism of Action
NPY exerts its effects primarily through five G-protein-coupled receptor subtypes (Y1, Y2, Y4, Y5, and Y6), with Y1 and Y5 receptors mediating appetite stimulation and energy intake, and Y2 receptors acting as inhibitory autoreceptors that modulate NPY release in the hypothalamus and hippocampus. Activation of Y1 receptors in the arcuate nucleus of the hypothalamus inhibits adenylyl cyclase, reducing cAMP levels and promoting feeding behavior while suppressing energy expenditure. Centrally, NPY also modulates HPA axis activity, dampens corticotropin-releasing factor signaling, and enhances GABAergic tone, contributing to its stress-buffering and anxiolytic effects.
Evidence by Health Goal(18 goals)
Dosing Protocols
Morning or during acute stress exposure; some protocols use pre-sleep administration for anxiolytic effects
Cycle: Limited to short-term research protocols; cycling not well established
Intranasal delivery is the most practically studied non-invasive route for central NPY effects. Formulation requires specialized nasal spray preparation with appropriate pH buffering. Evidence from human clinical trials (e.g., Yehuda et al.) suggests anxiolytic and stress-resilience effects at these doses.
Variable; typically administered in controlled experimental settings
Cycle: Research use only; no established human cycling protocol
Intracerebroventricular administration is restricted to preclinical animal models. Peripheral subcutaneous or intravenous injection in human research is investigational and requires clinical oversight. Peripheral NPY has limited CNS penetration due to blood-brain barrier constraints, limiting central efficacy via this route.
Safety & Side Effects
NPY is an endogenous human peptide with a generally favorable acute safety profile at research doses, particularly via the intranasal route; however, its chronic use carries meaningful metabolic risks including weight gain and cardiovascular effects due to widespread receptor distribution. Human research is still limited, and NPY is not an approved therapeutic agent in any jurisdiction — its use is confined to clinical research settings and requires ethical oversight and medical supervision.
Possible Side Effects
- !Increased appetite and hyperphagia with central or repeated dosing
- !Transient nasal mucosal irritation or congestion with intranasal administration
- !Vasoconstrictive effects peripherally, including transient blood pressure elevation
- !Sedation or drowsiness, particularly at higher doses via nasal route
- !Headache following intranasal dosing in some subjects
- !Potential promotion of adipogenesis and weight gain with chronic exposure
- !Bradycardia or heart rate variability changes due to cardiac Y1/Y2 receptor activation
Interactions
- -May potentiate antihypertensive medications by modulating sympathetic tone, but can paradoxically cause vasoconstriction via peripheral Y1 receptors — use with caution alongside antihypertensives
- -May enhance sedative or anxiolytic effects of benzodiazepines and GABAergic agents due to overlapping anxiolytic pathways
- -Leptin and insulin suppress endogenous NPY release — exogenous NPY administration may counteract appetite-suppressing effects of these hormones
- -Concurrent use with orexigenic agents (e.g., ghrelin analogs, cannabis-derived compounds) may produce additive hyperphagia
- -May interfere with corticotropin-releasing hormone (CRH) antagonist therapies by downregulating HPA axis activity through overlapping stress-response pathways
Cost & Where to Buy
Research-grade synthetic NPY (36 amino acids) is commercially available from peptide synthesis vendors at approximately $50-200 per 1mg vial depending on purity (>95% HPLC). Monthly cost depends heavily on dose and frequency; intranasal formulation preparation may add compounding costs. No pharmaceutical-grade human product is commercially approved.
Search on Amazon